Catalyst Pharmaceuticals, Inc.
CPRX
Clasificación en acciones
#4171
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Precio por acción
$31.49
Última sincronización: 2026-07-21
Capitalización bursátil
$3.85B
Cambio (1 día)
0.00%
Cambio (1 año)
49.88%
País
US
Comercio Catalyst Pharmaceuticals, Inc. (CPRX)
Categoría
Healthcare
Ganancias de Catalyst Pharmaceuticals, Inc. (CPRX)
Ganancias en Mar 2026 TTM: $296.46M
Secondo gli ultimi rapporti finanziari di Catalyst Pharmaceuticals, Inc., gli utili attuali della società sono $296.46M. Nel 2023, la società ha registrato un utile di $94.51M, una disminución en comparación con agli utili del 2022, che erano di $104.72M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Catalyst Pharmaceuticals, Inc. desde 2002 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $296.46M | 37.08% |
| 2024 | $216.26M | 128.82% |
| 2023 | $94.51M | -9.75% |
| 2022 | $104.72M | 98.83% |
| 2021 | $52.67M | 25.73% |
| 2020 | $41.89M | 25.39% |
| 2019 | $33.41M | -198.25% |
| 2018 | $-34.00M | 84.68% |
| 2017 | $-18.41M | 1.88% |
| 2016 | $-18.07M | -10.68% |
| 2015 | $-20.23M | 30.46% |
| 2014 | $-15.51M | 27.60% |
| 2013 | $-12.15M | 198.17% |
| 2012 | $-4.08M | -36.22% |
| 2011 | $-6.39M | 59.52% |
| 2010 | $-4.01M | -44.68% |
| 2009 | $-7.24M | -31.45% |
| 2008 | $-10.56M | 155.21% |
| 2007 | $-4.14M | 51.66% |
| 2006 | $-2.73M | 51.18% |
| 2005 | $-1.81M | 234.44% |
| 2004 | $-539.82K | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-255.95K | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 1,679.31% |
US
|
|
| $-3.09B | -1,141.29% |
US
|
|
| $-4.02B | -1,454.73% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 557.99% |
NL
|
